Shares of Kite Pharma, Inc. (NASDAQ: KITE) have had an impressive run so far this year riding on the progress of its revolutionary CAR-T therapy so far this year. The biopharmaceutical company’s ...
Kite Pharma, Inc. (NASDAQ:KITE) announced encouraging top-line data from a pre-planned interim analysis of a pivotal phase II portion of the ZUMA-1 study on its lead pipeline candidate, KTE-C19 (an ...
Kite Pharma ($KITE) has posted an interim analysis of Phase II CAR-T data it thinks are strong enough to support regulatory approval. The CAR-T triggered complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results